WO2023037268 - LINKERS FOR USE IN ANTIBODY DRUG CONJUGATES
National phase entry:
Publication Number
WO/2023/037268
Publication Date
16.03.2023
International Application No.
PCT/IB2022/058428
International Filing Date
07.09.2022
Title **
[English]
LINKERS FOR USE IN ANTIBODY DRUG CONJUGATES
[French]
LIEURS DESTINÉS À ÊTRE UTILISÉS DANS DES CONJUGUÉS ANTICORPS-MÉDICAMENT
Applicants **
ORUM THERAPEUTICS, INC.
2F, 281-25, Munji-ro
Yuseong-gu
Daejeon 34050, KR
Inventors
FISHKIN, Nathan
Orum Therapeutics, Ipsen Innovation Center/Biolabs
650 East Kendall St.
Cambridge, Massachusetts 02142, US
BAI, Chen
Orum Therapeutics, Ipsen Innovation Center/Biolabs
650 East Kendall St.
Cambridge, Massachusetts 02142, US
TAKROURI, Khuloud
Orum Therapeutics, Ipsen Innovation Center/Biolabs
650 East Kendall St.
Cambridge, Massachusetts 02142, US
PARK, Peter U.
Orum Therapeutics, Ipsen Innovation Center/Biolabs
650 East Kendall St.
Cambridge, Massachusetts 02142, US
Priority Data
63/241,914
08.09.2021
US
63/293,591
23.12.2021
US
63/351,639
13.06.2022
US
63/374,282
01.09.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
MOIP
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 6450 | |
| EPO | Filing, Examination | 77750 | |
| Japan | Filing | 588 | |
| South Korea | Filing | 671 | |
| USA | Filing, Examination | 27960 |
Total: 113419 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure provides traceless linkers, which can link an inducer of protein-protein interaction to a cell binding agent. Also provided are compositions comprising the linked compounds. The compounds and compositions are useful for treating diseases such as cancer in subjects in need thereof.[French]
La présente divulgation concerne des lieurs sans trace, qui peuvent lier un inducteur d'interaction protéine-protéine à un agent de liaison cellulaire. La divulgation concerne également des compositions comprenant les composés liés. Les composés et les compositions sont utiles pour traiter des maladies telles que le cancer chez des sujets en ayant besoin.